Clinical outcomes of liposomal irinotecan in advanced pancreatic adenocarcinoma patients previously treated with conventional irinotecan-based chemotherapy: a real-world study

BACKGROUND: The efficacy of combination chemotherapy beyond the first-line setting remains modest in patients with advanced pancreatic adenocarcinoma (PAC). Evidence from recent clinical studies has shown that liposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU) and leucovorin (LV) resulted in...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Amol, De Jesus-Acosta, Ana, Zheng, Lei, Lee, Valerie, Kamel, Ihab, Le, Dung, Pishvaian, Michael, Laheru, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10494436/
https://www.ncbi.nlm.nih.gov/pubmed/37700832
http://dx.doi.org/10.3389/fonc.2023.1250136

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10494436/
https://www.ncbi.nlm.nih.gov/pubmed/37700832
http://dx.doi.org/10.3389/fonc.2023.1250136

Ejemplares similares